Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ABEONA THERAPEUTICS INC. (ABEO)

Abeona Therapeutics Q2 ZEVASKYN revenue up 31% to $11.4 million; net loss $20.2 million

Mixed Impact 3 of 5 earnings Written later

Abeona Therapeutics reported second quarter 2026 net ZEVASKYN revenue of $11.4 million, up 31% from $8.7 million in the first quarter, while its net loss widened to $20.2 million, or $0.35 per share, from $17.1 million in the prior quarter. The company ended the quarter with $146.8 million in cash and short-term investments, down from $191.4 million at December 31, 2025, and said ZEVASKYN will have CMS NTAP status effective October 1, 2026.

Key points

  • Net ZEVASKYN revenue rose 31% quarter over quarter to $11.4 million; revenue was recognized for four of the five patients treated in the quarter
  • Net loss was $20.2 million, or $0.35 per share, versus $17.1 million, or $0.30 per share, in Q1 2026
  • Cash, cash equivalents and short-term investments totaled $146.8 million as of June 30, 2026, versus $191.4 million at December 31, 2025
  • ZEVASKYN receives CMS New Technology Add-On Payment status effective October 1, 2026

The filing

CompanyABEONA THERAPEUTICS INC. (ABEO)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:30 AM ET
Accession number0001493152-26-037575

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.